De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Microbix Biosystems Toekomstige groei
Future criteriumcontroles 2/6
De omzet Microbix Biosystems zal naar verwachting groeien met 22.7% per jaar. De winst per aandeel zal naar verwachting groeien met 23.1% per jaar.
Belangrijke informatie
n/a
Groei van de winst
23.1%
Groei van de winst per aandeel
Biotechs winstgroei | 38.7% |
Inkomstengroei | 22.7% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 15 Aug 2024 |
Recente toekomstige groei-updates
Microbix Biosystems Inc. (TSE:MBX) Just Reported Earnings, And Analysts Cut Their Target Price
Feb 17Recent updates
Microbix Biosystems' (TSE:MBX) Shareholders Should Assess Earnings With Caution
Aug 22Why Microbix Biosystems' (TSE:MBX) Earnings Are Weaker Than They Seem
Feb 21Microbix Biosystems Inc. (TSE:MBX) Just Reported Earnings, And Analysts Cut Their Target Price
Feb 17Microbix Biosystems Inc.'s (TSE:MBX) Shares Climb 29% But Its Business Is Yet to Catch Up
Dec 23Is Microbix Biosystems (TSE:MBX) Using Debt Sensibly?
Nov 03Is Microbix Biosystems (TSE:MBX) Using Debt In A Risky Way?
Jul 22Some Shareholders Feeling Restless Over Microbix Biosystems Inc.'s (TSE:MBX) P/S Ratio
May 17Time To Worry? Analysts Are Downgrading Their Microbix Biosystems Inc. (TSE:MBX) Outlook
Dec 27Microbix Biosystems (TSE:MBX) Has A Pretty Healthy Balance Sheet
Aug 08Microbix Biosystems' (TSE:MBX) Solid Profits Have Weak Fundamentals
May 20Microbix Biosystems (TSE:MBX) Seems To Use Debt Quite Sensibly
Feb 06One Microbix Biosystems Inc. (TSE:MBX) Analyst Just Made A Major Cut To Next Year's Estimates
Dec 28Is Microbix Biosystems (TSE:MBX) A Risky Investment?
Oct 14Microbix Biosystems Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 15A Look At The Fair Value Of Microbix Biosystems Inc. (TSE:MBX)
May 17Most Shareholders Will Probably Find That The CEO Compensation For Microbix Biosystems Inc. (TSE:MBX) Is Reasonable
Mar 24We Think Microbix Biosystems (TSE:MBX) Has A Fair Chunk Of Debt
Jan 29Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
9/30/2026 | 39 | N/A | N/A | N/A | 1 |
9/30/2025 | 29 | N/A | N/A | N/A | 1 |
9/30/2024 | 25 | N/A | N/A | N/A | 1 |
6/30/2024 | 23 | 5 | 0 | 2 | N/A |
3/31/2024 | 24 | 4 | 2 | 3 | N/A |
12/31/2023 | 22 | 4 | 0 | 1 | N/A |
9/30/2023 | 17 | 0 | -2 | -1 | N/A |
6/30/2023 | 17 | -3 | -2 | 1 | N/A |
3/31/2023 | 16 | -1 | -1 | 1 | N/A |
12/31/2022 | 17 | 0 | 1 | 3 | N/A |
9/30/2022 | 19 | 2 | 1 | 3 | N/A |
6/30/2022 | 20 | 3 | 4 | 5 | N/A |
3/31/2022 | 21 | 4 | 1 | 2 | N/A |
12/31/2021 | 20 | 4 | 1 | 2 | N/A |
9/30/2021 | 19 | 3 | 1 | 2 | N/A |
6/30/2021 | 16 | -3 | -1 | 0 | N/A |
3/31/2021 | 13 | -4 | 0 | 2 | N/A |
12/31/2020 | 12 | -6 | -1 | 0 | N/A |
9/30/2020 | 11 | -6 | -1 | 0 | N/A |
6/30/2020 | 11 | -1 | 0 | 1 | N/A |
3/31/2020 | 12 | -1 | -1 | 0 | N/A |
12/31/2019 | 13 | 0 | 0 | 0 | N/A |
9/30/2019 | 13 | 0 | 0 | 0 | N/A |
6/30/2019 | 13 | -8 | 0 | 0 | N/A |
3/31/2019 | 13 | -8 | 0 | 0 | N/A |
12/31/2018 | 12 | -9 | 0 | 1 | N/A |
9/30/2018 | 13 | -9 | -2 | -1 | N/A |
6/30/2018 | 12 | -1 | -2 | -1 | N/A |
3/31/2018 | 11 | -1 | N/A | -1 | N/A |
12/31/2017 | 11 | -1 | N/A | -1 | N/A |
9/30/2017 | 10 | -4 | N/A | 0 | N/A |
6/30/2017 | 11 | -2 | N/A | 1 | N/A |
3/31/2017 | 10 | -2 | N/A | 1 | N/A |
12/31/2016 | 10 | -2 | N/A | 1 | N/A |
9/30/2016 | 10 | 1 | N/A | 1 | N/A |
6/30/2016 | 8 | 0 | N/A | 1 | N/A |
3/31/2016 | 8 | 0 | N/A | 0 | N/A |
12/31/2015 | 8 | 0 | N/A | 0 | N/A |
9/30/2015 | 9 | 1 | N/A | 1 | N/A |
6/30/2015 | 9 | 0 | N/A | 0 | N/A |
3/31/2015 | 9 | 0 | N/A | 0 | N/A |
12/31/2014 | 8 | 0 | N/A | -1 | N/A |
9/30/2014 | 8 | 0 | N/A | -1 | N/A |
6/30/2014 | 9 | 1 | N/A | 1 | N/A |
3/31/2014 | 8 | 1 | N/A | 1 | N/A |
12/31/2013 | 9 | 1 | N/A | 0 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van MBX boven de spaarquote ( 2.2% ) ligt.
Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van MBX naar verwachting sneller zal groeien dan de markt Canadian
Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van MBX naar verwachting de komende 3 jaar aanzienlijk zal groeien.
Omzet versus markt: De omzet van MBX ( 22.7% per jaar) zal naar verwachting sneller groeien dan de markt Canadian ( 7% per jaar).
Hoge groei-inkomsten: De omzet van MBX ( 22.7% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van MBX naar verwachting over 3 jaar hoog zal zijn